Search results
- Dr. Sethuraman joined Entrada Therapeutics as Chief Scientific Officer in 2017 and leads global research and clinical development. He brings deep experience in drug discovery and development across multiple modalities including oligonucleotides, antibodies, therapeutic enzymes, and peptides.
www.biospace.com/press-releases/entrada-therapeutics-promotes-natarajan-sethuraman-phd-to-president-of-research-and-developmentEntrada Therapeutics Promotes Natarajan Sethuraman, PhD, to ...
People also ask
Who is Nadarajan sethuraju?
Who is Suresh Natarajan?
Who is S N Sethuram?
Who was N Natarajan?
Natarajan Sethuraman, PhD President of Research and Development BOSTON, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines.
4 days ago · Prior to Entrada, Dr. Sethuraman was at Merck & Co., Inc. where he led the GlycoFi site as well as the research and development of novel biologics following Merck’s acquisition of GlycoFi in 2006. He holds a PhD in Entomology, Molecular Biology and Biochemistry from the Indian Agricultural Research Institute, a BSc from Tamil Nadu Agricultural University and completed his post-doctoral training at Duke University.
4 days ago · “Natarajan has been with Entrada since our inception and his leadership has been invaluable in the research and clinical development of the company’s diverse pipeline of proprietary intracellular therapeutics,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. “His deep and broad experience in end-to-end therapeutics development has helped advance our ENTR-601-44 program into the clinic, build our pipeline, and establish a dedicated team driven by intellectual ...
Location: Hanover · 500+ connections on LinkedIn. View Natarajan Sethuraman’s profile on LinkedIn, a professional community of 1 billion members.
- 500+
- Hanover, New Hampshire, United States
Presently, Natarajan Sethuraman is Chief Scientific Officer for Entrada Therapeutics, Inc. In the past Dr. Sethuraman held the position of Executive Director & Head-GlycoFi Site at Merck & Co., Inc....
We’re excited to announce the promotion of our current Chief Scientific Officer, Natarajan Sethuraman, PhD, to President of Research and Development.
May 31, 2024 · Natarajan Sethuraman is currently the Chief Scientific Officer at Entrada Therapeutics, Inc. Previously, he worked at Merck & Co., Inc. as the Executive Director & Head-GlycoFi Site from 2012 to 2016. He also worked as a Senior Scientist at Medical Enzymes AG.
